Although the detailed mechanism is not clarified, CCL2 promotes invasion and adhesion of human ovarian cancer cells, and CCL2 blockade can enhance the cytotoxic effect of paclitaxel and carboplatin therapies in ovarian cancer [36,37]. This evidence concerns the gene CCL2 and ovarian carcinoma.